Skip to content
IP + Technology Law
Home  »  News & Insights  »  News

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States

October 20, 2014  | Joseph Mallon, Ph.D., Ryan E. Melnick, Ph.D., Kimberly J. Miller, Ph.D., Agnes Juang, Ph.D., Kerry S. Taylor, Ph.D., William Zimmerman, Rose M. Thiessen, Ph.D., Jing Liu, Jane Dai, Ph.D., Nathanael Luman, Ph.D., Victor C. Vassar and Vijay Gore, Ph.D.

Read the full press release here.

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Joseph Mallon, Ph.D.
Partner
San Diego
joseph.mallon@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Ryan E. Melnick, Ph.D.
Partner
San Diego
ryan.melnick@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Kimberly J. Miller, Ph.D.
Partner
San Diego
kimberly.miller@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Agnes Juang, Ph.D.
Partner
Orange County
agnes.juang@knobbe.com
949-760-0404
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

William Zimmerman
Partner
Washington DC
bill.zimmerman@knobbe.com
202-640-6400
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Jane Dai, Ph.D.
Partner
San Diego
jane.dai@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Nathanael Luman, Ph.D.
Partner
San Diego
nate.luman@knobbe.com
858-707-4000

Related Links

Industries

News & Insights

News
Jan 2026
Knobbe Martens Again Receives Top Recognition in World Trademark Review 1000 Guide
IRVINE, Calif., January 30, 2026 – Knobbe Martens is pleased to share that the firm’s Trademark and Brand Protection practice and ten of its partners have once again been recognized...
Publications
Feb 2026
Knobbe Martens Partners Outline Major USPTO Policy Shifts in Law360 Article
In a recent Law360 article, Knobbe Martens partners Rosaleen Chou, Ted Cannon, and Philip Nelson highlight significant policy developments at the U.S. Patent and Trademark Office (USPTO) expected to shape...
News
Jan 2026
Knobbe Martens Advises Conformal Medical on Definitive Agreement To Be Acquired by W. L. Gore & Associates
IRVINE, Calif., January, 8, 2026 – W. L. Gore & Associates, Inc. (Gore) a global materials science company dedicated to transforming industries and improving lives, announced this week that it...